Cockrell Group
Long only, deep value, value, growth at reasonable price

Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook

We are remaining positive on the outlook of Supernus Pharmaceuticals' (NASDAQ:SUPN) shares after the Company released its 4Q13 and FY2013 results. Reported revenues for 2013 were approximately $12 million, which exceeded analyst estimates of $8.3 million. Shares of the company closed up 2.62% at $9.15 on Mar...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.